Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer

Cancer Investigation

Volumn 31, Issue 8, 2013, Pages 516-521

  Won, Hye Sung ^a   Kim, Young Ae ^b   Lee, Jun Sang ^a   Jeon, Eun Kyoung ^b   An, Ho Jung ^a   Sun, Der Sheng ^a   Ko, Yoon Ho ^a   Kim, Jeong Soo ^a  

^a Uijeongbu St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Breast cancer; Interleukin 6; Prognosis; Soluble interleukin 6 receptor

Indexed keywords

GLYCOPROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SOLUBLE GLYCOPROTEIN 130; SOLUBLE INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; COLLOID CARCINOMA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYTOKINE RECEPTOR GP130; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, INTERLEUKIN-6; TUMOR MARKERS, BIOLOGICAL;

EID: 84885119988     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.826239     Document Type: Article

References (21)

1. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010;46:1223-1231.
2. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. Thesoluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011;90:484-494.
3. Rose-John S,Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007;11:613-624.
4. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algul H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-469.
5. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007;21: 1714-1719.
6. Fan Y, Ye J, Shen F, Zhu Y, Yeghiazarians Y, Zhu W, Chen Y, LawtonMT, Young WL, Yang GY. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008;28:90-98.
7. Egler RA, Burlingame SM, Nuchtern JG, Russell HV. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin Cancer Res 2008;14: 7028-7034.
8. Shariat SF,KattanMW,Traxel E,Andrews B, Zhu K,Wheeler TM, Slawin KM. Association of pre-and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptorwithprostate cancer progression. ClinCancerRes 2004;10:1992-1999.
9. Smith SR, Morgan L. Clinical significance of elevated soluble interleukin 6 receptor levels in patients with plasma cell disorders. Br J Haematol 1996;92:767-768.
10. Wierzbowska A, Urbanska-Rys H, Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol 1999;105:412-419.
11. Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, D'Alessandro N, Montalto G. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci 2002;963:46-52.
12. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4:217-220.
13. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 2000;7:187-190.
14. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999;19:1427-1432.
15. Kovacs E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 2001;55:391-396.
16. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21: 491-501.
17. Gameiro CM, Romao F, Castelo-Branco C. Menopause and aging: changes in the immune system-A review. Maturitas 2010;67: 316-320.
18. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN, Gram J, Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2000;15:1545-1554.
19. Girasole G, Giuliani N,Modena AB, Passeri G, Pedrazzoni M. Oestrogens prevent the increase of human serumsoluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin Endocrinol (Oxf) 1999;51:801-807.
20. Polgar A, Brozik M, Toth S, Holub M, Falus A. A synthetic corticosteroid, dexamethasone regulates generation of soluble form of interleukin-6 receptor of human lymphocytes, in vitro. Acta Biol Hung 2002;53:307-315.
21. Mori S, Murakami-Mori K, Bonavida B. Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines. Anticancer Res 1998;18: 4403-4408.